Page 134 - 南京医科大学学报自然科学版
P. 134

第43卷第1期
               ·128 ·                            南 京    医 科 大 学 学         报                        2023年1月


              孕前、孕期及哺乳期新冠疫苗接种的安全性研究进                                 1423
              展基于目前已有的案例研究以及小规模、短时间的                            [11] POLACK F P,THOMAS S J,KITCHIN N,et al. Safety
              队列研究报道,在 3 类人群中接种最多的是 mRNA                             and efficacy of the BNT162b2 mRNA covid⁃19 vaccine
              疫苗,主要出现一系列轻度不良反应,如注射部位                                [J]. N Engl J Med,2020,383(27):2603-2615
                                                                [12] LOGUNOV D Y,DOLZHIKOVA I V,SHCHEBLYAKOV
              疼痛、发热、疲劳、恶心、呕吐等;其次是腺病毒疫
                                                                     D V,et al. Safety and efficacy of an rAd26 and rAd5 vec⁃
              苗,不仅出现一系列轻度不良反应,还出现血栓等
                                                                     tor⁃based heterologous prime⁃boost COVID⁃19 vaccine:
              风险。但未来对于新冠疫苗对孕前、孕期及哺乳期
                                                                     an interim analysis of a randomised controlled phase 3 tri⁃
              的安全性评估仍需要多中心、大样本队列的深入研
                                                                     al in Russia[J]. Lancet,2021,397(10275):671-681
              究。                                                [13] DE HAAN P,VAN DIEMEN F R,TOSCANO M G. Viral
             [参考文献]                                                  gene delivery vectors:the next generation medicines for
                                                                     immune⁃related diseases[J]. Hum Vaccin Immunother,
             [1] WORLD HEALTH ORGANIZATION. WHO Coronavirus
                                                                     2021,17(1):14-21
                  (COVID ⁃ 19) Dashboard[EB/OL]. [2022- 04- 07].
                                                                [14] KIM E,ERDOS G,HUANG S,et al. Microneedle array
                   https://covid19.who.int/
                                                                     delivered recombinant coronavirus vaccines:Immunoge⁃
             [2] WORLD HEALTH ORGANIZATION. COVID ⁃ 19 vac⁃
                                                                     nicity and rapid translational development[J]. EBioMedi⁃
                   cine tracker and landscape[EB/OL]. [2022- 04- 07].
                                                                     cine,2020,55:102743
                   https://www.who.int/publications/m/item/draft⁃landscape⁃
                                                                [15] ROYAL SOCIETY OF CHEMISTRY. Protein⁃based COV⁃
                   of⁃covid⁃19⁃candidate⁃vaccines
                                                                     ID⁃19 vaccines could overshadow rivals[EB/OL].[2022-
             [3] BERRY S D,JOHNSON K S,MYLES L,et al. Lessons
                                                                     04- 26]. https://www.chemistryworld.com/news/protein ⁃
                   learned from frontline skilled nursing facility staff regard⁃
                                                                     based ⁃ covid ⁃ 19 ⁃ vaccines ⁃ could ⁃ overshadow ⁃ rivals/
                   ing COVID⁃19 vaccine hesitancy[J]. J Am Geriatr Soc,
                                                                     4012450.article
                   2021,69(5):1140-1146
                                                                [16] NEIL G,VIKI B,STEPHAN B,et al. Safety and immuno⁃
             [4] DELAHOY M J,WHITAKER M,O’HALLORAN A,et al.
                                                                     genicity of heterologous and homologous two dose regi⁃
                   Characteristics and maternal and birth outcomes of hospi⁃
                                                                     mens of AD26⁃and MVA⁃vectored Ebola vaccines:a ran⁃
                   talized pregnant women with laboratory⁃confirmed COVID  domized,controlled phase 1 study[J]. J Infect Dis,2022,
                   ⁃19⁃COVID⁃NET,13 states,March 1⁃August 22,2020[J].
                                                                     226(4):595-607
                   MMWR Morb Mortal Wkly Rep,2020,69(38):1347-
                                                                [17] HOTEZ P J,BOTTAZZI M E. Developing a low⁃cost and
                   1354
                                                                     accessible COVID⁃19 vaccine for global health[J]. PLoS
             [5] PLOTKIN S. History of vaccination[J]. Proc Natl Acad
                                                                     Negl Trop Dis,2020,14(7):e0008548
                   Sci U S A,2014,111(34):12283-12287
                                                                [18] FIERCE P. Pfizer,moderna’s coronavirus shot rollouts
             [6] ZHOU J,WANG W,ZHONG Q,et al. Immunogenicity,
                                                                     could freeze up,experts say,citing cold ⁃ storage needs
                   safety,and protective efficacy of an inactivated SARS⁃as⁃
                                                                     [EB/OL]. [2022- 04- 26]. https://www.fiercepharma.
                   sociated coronavirus vaccine in rhesus monkeys[J]. Vac⁃
                                                                     com/manufacturing/pfizer⁃moderna⁃s⁃covid⁃19⁃shot⁃roll⁃
                   cine,2005,23(24):3202-3209
                                                                     outs⁃could⁃be⁃ice⁃as⁃analysts⁃question⁃cold
             [7] SPRUTH M,KISTNER O,SAVIDIS⁃DACHO H,et al. A
                                                                [19] DUNKLE L M,KOTLOFF K L,GAY C L,et al. Efficacy
                   double⁃inactivated whole virus candidate SARS coronavi⁃  and safety of NVX ⁃ CoV2373 in adults in the United
                   rus vaccine stimulates neutralising and protective anti⁃  States and Mexico[J]. N Engl J Med,2022,386(6):531-
                   body responses[J]. Vaccine,2006,24(5):652-661     543
             [8] JACKSON N A C,KESTER K E,CASIMIRO D,et al.     [20] STEPHENSON J,HESLEHURST N,HALL J,et al. Be⁃
                   The promise of mRNA vaccines:a biotech and industrial  fore the beginning:nutrition and lifestyle in the precon⁃
                   perspective[J]. NPJ Vaccines,2020,5:11            ception period and its importance for future health[J].
             [9] BADEN L R,EL SAHLY H M,ESSINK B,et al. Efficacy     Lancet,2018,391(10132):1830-1841
                   and safety of the mRNA⁃1273 SARS⁃CoV⁃2 vaccine[J].  [21] RESCHINI M,PAGLIARDINI L,BOERI L,et al. COVID⁃
                   N Engl J Med,2021,384(5):403-416                  19 vaccination does not affect reproductive health parame⁃
             [10] DAGAN N,BARDA N,KEPTEN E,et al. BNT162b2           ters in men[J]. Front Public Health,2022,10:839967
                   mRNA COVID⁃19 vaccine in a nationwide mass vaccina⁃  [22] LIFSHITZ D,HAAS J,LEBOVITZ O,et al. Does mRNA
                   tion setting[J]. N Engl J Med,2021,384(15):1412-  SARS⁃CoV⁃2 vaccine detrimentally affect male fertility,
   129   130   131   132   133   134   135   136   137   138   139